Trials on new islet cell therapy offer potential to reduce or stop insulin use for people with type 1 diabetes
VX-880 has been generally well tolerated in all patients dosed to date, with mild or moderate adverse reactions, such as dehydration, diarrhoea, hypomagnesemia and rash.
As a result of these safety reports a third trial period is anticipated, with dosing of patients at the full target dose of VX-880.
Felicia Pagliuca, Ph.D., Disease Area Executive, Type 1 Diabetes at Vertex, said: “These data represent a foundational advance in the potential treatment of T1D, bringing us one step closer to a potentially curative therapy for patients who are waiting.”
Trevor Reichman, M.D., Department of Surgery, University of Toronto, said: “The normalisation of HbA1c without the need for exogenous insulin one year after therapy with VX-880 is historic and offers hope that the transformative therapies the type 1 diabetes community has been waiting for may finally become reality.”
Professor Ricordi said: “In addition to the VX-880 trial we are happy that the VX-264 trial is now enrolling. This is an investigational cell therapy in which allogeneic human stem cell-derived islets similar to those used in the VX-880 trial are encapsulated in a channel array device designed to shield the cells from the body’s immune system. VX-264 is designed to be surgically implanted and is currently being evaluated for patients with T1D, without any anti-rejection drugs (immunosuppression).”
Find out more about type 1 diabetes
I would like to make a regular donation of
I would like to make a single donation of